


SEQUENTIAL DESIGN OF EXPERIMENTS FOR PERSONALIZED MEDICINE




Mia Sato Tackney¹, Prof. Dave Woods¹, Dr. Kim May Lee², Dr. Ilya Shpitser³, Prof. Peter WF Smith¹

¹University of Southampton ²MRC Biostatistics Unit, University of Cambridge ³Johns Hopkins University


PERSONALIZED MEDICINE

Advances in genomics are making it possible to tailor treatment recommendations based on individual patient characteristics. In a personalized clinical trial, patients are stratified into subgroups based on their **biomarker** profile. We wish to identify **effective treatment-biomarker combinations**.



Assume that there are n patients arriving sequentially for the trial, k binary biomarkers and a binary treatment factor. We need a way of allocating treatments to patients which is:

1. Sequential.
2. Able to estimate interaction effects corresponding to effective treatment-biomarker combinations as efficiently as possible.



We compare myopic and non-myopic approaches. **DOES TAKING INTO ACCOUNT FUTURE POSSIBLE PATIENTS IMPROVE EFFICIENCY?**

OPTIMAL DESIGN OF EXPERIMENTS

We use a logistic model for the response:

$$y_i \sim \text{Bernoulli}(\pi_i), \text{ where } \text{logit}\left(\frac{\pi_i}{1-\pi_i}\right) = \mathbf{x}_i^T \boldsymbol{\beta},$$

where \mathbf{x}_i is the i th row of design matrix \mathbf{X} with includes columns corresponding to effects for all biomarkers, treatments and biomarker-treatment interactions. We aim to test $R = 2^k$ hypotheses:

$$H_0: \mathbf{c}_r^T \boldsymbol{\beta} \geq \tau_r \quad \text{vs} \quad H_1: \mathbf{c}_r^T \boldsymbol{\beta} < \tau_r,$$

where \mathbf{c}_r are vectors in $\{0, 1\}^p$ to indicate **linear combinations of interest**, and τ_r is a threshold for the minimum interesting treatment difference, for $r \in \{1, \dots, R\}$. We define weights:

$$w_r = P(\mathbf{c}_r^T \hat{\boldsymbol{\beta}} < \tau_r).$$

We use a **weighted L -optimal objective function** proposed by Lee and Wason (2019) to minimize the variance of successful $\mathbf{c}_r^T \hat{\boldsymbol{\beta}}$:

$$\Psi_L(\mathbf{X}) = \left(\sum_{r=1}^R w_r \mathbf{c}_r^T (\mathbf{X}^T \mathbf{W} \mathbf{X})^{-1} \mathbf{c}_r \right)^{-1},$$

where \mathbf{W} is a diagonal matrix with i th entry equal to $\hat{\pi}_i(1 - \hat{\pi}_i)$


$$\text{where } \hat{\pi}_i = \frac{\hat{\beta} x_i}{1 + \hat{\beta} x_i}.$$

A MYOPIC ALGORITHM FOR SEQUENTIAL L -OPTIMAL DESIGN

- Construct an initial design with n_0 patients which minimizes Ψ_L , assuming equal weights.
- Observe initial responses y_1, \dots, y_{n_0} .
- Fit the model to obtain $\hat{\boldsymbol{\beta}}_0$.
- Compute weights $w_{r_0} = P(\mathbf{c}_r^T \hat{\boldsymbol{\beta}}_0 < \tau_r)$.
- For i in $n_0 + 1$ to n , given biomarker profile of patient i :
 1. Calculate the weighted L -optimal objective function for the design $\mathbf{X}_{i,t}$ with i patients where patient i gets treatment t , for $t \in \{0, 1\}$, using $\hat{\boldsymbol{\beta}}_{i-1}$ to compute $\mathbf{W}_i: \Psi_L(\mathbf{X}_{i,t}) = \left(\sum_{r=1}^R w_{r,i-1} \mathbf{c}_r^T (\mathbf{X}_{i,t}^T \mathbf{W}_{i-1} \mathbf{X}_{i,t})^{-1} \mathbf{c}_r \right)^{-1}$.
 2. Sample the treatment for patient i . The probability of selecting treatment 1 is:
$$\frac{\Psi_L(\mathbf{X}_{i,t=1})}{\Psi_L(\mathbf{X}_{i,t=0}) + \Psi_L(\mathbf{X}_{i,t=1})}.$$
 3. Observe response y_i and refit the model to obtain $\hat{\boldsymbol{\beta}}_i$.

A NON-MYOPIC APPROACH

A non-myopic approach to designing sequential experiments considers the impact of the choice of treatment for patient i on **future possible patients**. Our non-myopic algorithm generates M possible **trajectories** of biomarker values for patient $i + 1$ up to patient n from an assumed distribution of the biomarkers. We select treatments for the future possible patients in the trajectory and choose a treatment based on the efficiency of the M designs each containing i real patients and $n - i$ simulated patients.



CHANGE STEPS 2 AND 3 THE ALGORITHM:


2. For m in 1 to M :
 - a. From the assumed biomarker distribution, generate biomarkers for patients $i + 1$ to n .
 - b. Assuming that patient i gets treatment t , for $t \in \{0, 1\}$, sequentially select the treatment which minimizes the L -optimality criterion for the future patients. Denote the resulting design matrix by $\mathbf{X}_{i,t}^m$. Compute:
$$\Psi_L(\mathbf{X}_{i,t}^m) = \left(\sum_{r=1}^R w_{r,i-1} \mathbf{c}_r^T (\mathbf{X}_{i,t}^{mT} \mathbf{W}_{i-1} \mathbf{X}_{i,t}^m)^{-1} \mathbf{c}_r \right)^{-1}.$$
 - c. For $t \in \{0, 1\}$, compute $\bar{\Psi}_L(t_i = t) = \frac{1}{M} \sum_{m=1}^M \Psi_L(\mathbf{X}_{i,t}^m)$
3. Sample the treatment for patient i , where the probability of selecting treatment is:
$$\frac{\bar{\Psi}_L(t_i=1)}{\bar{\Psi}_L(t_i=1) + \bar{\Psi}_L(t_i=0)}.$$

Note: Step (b) can be done with a coordinate exchange algorithm instead of sequentially.

RESULTS

WE FIND THAT THE MYOPIC APPROACH IS MORE EFFICIENT THAN THE NON-MYOPIC APPROACH.

- EXAMPLE:**
- Two biomarkers with distributions Bernoulli(0.5) and Bernoulli(0.7)
 - New treatment better than control, especially in second biomarker group
 - 100 patients ➤ initial sample size 15 ➤ 100 simulations



Proportion of patients assigned to treatment 1 against sample size
• < 0.5 • > 0.5

Distribution of L -optimality of the design against sample size
 — Median — 40%-60% — 10%-90%

We also found this result to be true for the linear and logistic model case, for D - and L -optimality, for time-varying and static biomarkers, and for binary and continuous treatment factors.

REFERENCES

- Atkinson, A. C. (1982) Optimum biased coin designs for sequential clinical trials with prognostic factors. *Biometrika*, **69**, 61–67.
 Lee, K.M. and Watson, J. (2019) Design of experiments for a confirmatory trial of precision medicine. *Journal of Statistical Planning and Inference*, **199**, 179–187.

